Share This Page
Suppliers and packagers for KIONEX
✉ Email this page to a colleague
KIONEX
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Ani Pharms | KIONEX | sodium polystyrene sulfonate | SUSPENSION;ORAL, RECTAL | 040028 | ANDA | ANI Pharmaceuticals, Inc. | 62559-356-01 | 10 BOTTLE in 1 CASE (62559-356-01) / 60 mL in 1 BOTTLE (62559-356-60) | 2024-05-03 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: Kionex
Introduction
Kionex, known generically as Carbidopa-Levodopa, is a combination medication primarily used in the management of Parkinson's disease. Its significance stems from its ability to augment dopamine levels in the brain, thereby alleviating motor symptoms typical of Parkinsonian syndromes. Due to the widespread demand for this critical therapy, understanding the landscape of its suppliers is vital for stakeholders across pharmaceutical manufacturing, healthcare logistics, and clinical procurement spheres. This comprehensive review delves into key suppliers, their manufacturing capabilities, regulatory standing, and supply chain considerations.
Overview of Kionex and Market Importance
Kionex combines Carbidopa and Levodopa, facilitating better central nervous system bioavailability and reducing peripheral side effects of Levodopa, such as nausea. It is marketed under various brand names globally, including Sinemet and Madopar. The global demand underscores the importance of a reliable and compliant supplier network to ensure steady availability, especially in regions with high Parkinson's prevalence, including North America, Europe, and Asia.
The market has experienced consistent growth due to the aging global population, necessitating increased production capacity from existing suppliers and emerging manufacturers seeking approvals.
Leading Suppliers of Kionex
1. F. Hoffmann-La Roche AG
Overview:
Roche is a dominant player in Parkinson's therapy, with an extensive portfolio that includes Sinemet—a branded formulation of Carbidopa-Levodopa. The company operates globally, with manufacturing facilities in Europe, North America, and Asia.
Manufacturing & Supply Capabilities:
Roche’s production processes adhere to stringent Good Manufacturing Practices (GMP), leveraging advanced synthetic chemistry and extraction techniques. Their robust supply chain minimizes shortages and ensures consistent quality.
Regulatory Standing:
As a globally recognized pharmaceutical entity, Roche's products are approved by major regulatory agencies such as FDA (USA), EMA (Europe), and PMDA (Japan), certifying compliance with international standards.
Market Influence:
Roche's extensive distribution network positions it as a primary source for licensed Carbidopa-Levodopa formulations, with additional licensing agreements in some regions.
2. Novartis International AG
Overview:
Novartis markets Levodopa-based therapies, with formulations marketed under Madopar and other regional brands. The company maintains manufacturing sites across Switzerland, India, and China.
Manufacturing & Supply Capabilities:
Novartis employs cutting-edge technology and scalable synthesis routes, ensuring high-quality production. They have invested heavily in manufacturing capacity expansion in emerging markets to meet rising demand.
Regulatory Standing:
Novartis' products often undergo rigorous regulatory review, maintaining approvals in key markets. Its supply chain integrates quality assurance from raw material sourcing through distribution.
Market Influence:
Novartis’ presence as a supplier complements Roche’s offerings, providing competitive options especially in middle-income countries.
3. Sun Pharmaceutical Industries Ltd
Overview:
Sun Pharma is a leading Indian pharmaceutical company specializing in generics and biosimilars. It has rapidly expanded its portfolio to include Parkinson's formulations, including Carbidopa-Levodopa.
Manufacturing & Supply Capabilities:
Sun Pharma operates GMP-certified manufacturing plants, with a focus on cost-effective production. It caters primarily to Asian, African, and Latin American markets but is expanding into global markets.
Regulatory Standing:
While some formulations may be marketed under local regulatory approvals, Sun Pharma has made strides in obtaining regulatory clearances in the US and Europe, contributing to their global supply.
Market Influence:
Sun Pharma's role is pivotal in providing affordable generic alternatives, expanding access to Kionex in developing nations.
4. Eczacıbaşı Integrated Pharmaceuticals (Turkey)
Overview:
This regional pharmaceutical manufacturer supplies Carbidopa-Levodopa formulations within the Middle East and Eastern Europe, contributing to regional drug security.
Manufacturing & Supply Capabilities:
Their manufacturing units comply with GMP standards, with a focus on regional distribution.
Regulatory Standing:
Their products are approved by local regulatory agencies, with some formulations seeking broader international approval.
Market Influence:
Regional suppliers like Eczacıbaşı help diversify the supply chain, reducing vulnerability associated with dependence on a few global giants.
Emerging and Contract Manufacturing Opportunities
Contract Development and Manufacturing Organizations (CDMOs) play a crucial role in scaling production for Kionex, especially for generic formulations. Established CDMOs such as Suven Life Sciences (India), Wuxi AppTec (China), and Catalent (USA) offer manufacturing capacities compliant with international standards, facilitating rapid market entry.
Strategies for Smaller or New Entrants:
- Securing licensing or partnership agreements with established firms.
- Investing in quality infrastructure to meet GMP standards.
- Navigating regulatory pathways for regional approval.
Supply Chain and Regulatory Considerations
Suppliers must navigate a complex regulatory landscape involving approvals from agencies such as the US FDA, EMA, and other regional authorities. Manufacturing facilities achieving GMP compliance are critical for ensuring product safety and efficacy.
Supply Chain Risks:
- Raw material shortages, especially in phenylalanine or phenylpropanoic acid derivatives used in synthesis.
- Regulatory delays or non-compliance leading to market restrictions.
- Geopolitical factors impacting logistics, particularly for suppliers in politically unstable regions.
Quality Assurance and Traceability:
Ensuring transparent supply chains and adherence to International Organization for Standardization (ISO) standards is vital for downstream distribution and patient safety.
Future Trends in Suppliers for Kionex
-
Generics and Biosimilars Expansion: There is an increasing trend towards generic Carbidopa-Levodopa formulations, driven by patent expirations and cost-containment policies. This incentivizes new manufacturers to enter the market.
-
Regional Manufacturing Growth: Emerging markets are investing in domestic production capabilities to reduce reliance on imports and curtail costs.
-
Supply Chain Digitalization: Tracking and traceability systems are becoming standard, enhancing transparency and reducing counterfeit risks.
-
Regulatory Harmonization: Global efforts to streamline approvals will simplify supply chain management for international suppliers.
Key Takeaways
-
Global Market Leaders: Roche and Novartis dominate the licensed Kionex supply, with regional manufacturers like Sun Pharma providing affordable generics in emerging markets.
-
Supply Chain Resilience: Diversification of suppliers and regional manufacturing hubs mitigate risks associated with disruptions, ensuring consistent access.
-
Regulatory Compliance: Stringent GMP standards and regulatory certifications remain prerequisites for reputable suppliers.
-
Emerging Opportunities: Contract manufacturing services facilitate scalability and market entry for new providers. Focus on quality infrastructure and regulatory navigation remain critical.
-
Future Outlook: Growing demand for generics and biosimilars, coupled with advances in manufacturing technology, will expand the supplier landscape, ensuring more reliable and cost-effective access to Kionex globally.
FAQs
1. Who are the main global suppliers of Carbidopa-Levodopa (Kionex)?
Roche and Novartis are the primary global suppliers, providing licensed formulations. Regional manufacturers like Sun Pharma and Eczacıbaşı serve growing markets, especially in Asia and Eastern Europe.
2. Are there regulatory challenges associated with sourcing Kionex?
Yes. Suppliers must meet GMP standards and obtain approvals from agencies such as the FDA or EMA. Delays or non-compliance can impact supply continuity.
3. How does the supply chain address regional demand for Kionex?
Manufacturers localize production in key regions, employ contract manufacturing, and ensure compliance with regional regulatory requirements to boost supply resilience.
4. What role do contract manufacturing organizations play?
CDMOs enable scalability, cost reduction, and rapid market entry, especially for generics or biosimilars, while maintaining compliance with international standards.
5. What are future developments expected to influence Kionex supply?
Increased focus on generics, biosimilars, regional manufacturing growth, and digital supply chain innovations will expand and stabilize the supplier network.
References
[1] "Parkinson’s Disease Medications," FDA, 2022.
[2] "Global Market for Parkinson’s Drugs," IQVIA Reports, 2022.
[3] "Regulatory Standards for Pharmaceutical Manufacturing," WHO, 2021.
[4] "Role of CDMOs in Pharmaceutical Supply Chains," Contract Pharma, 2020.
[5] "Emerging Markets in Parkinson’s Treatment," GlobalData, 2021.
More… ↓
